KOMO Biosciences
San Diego, United States· Est.
A platform company delivering non‑viral, high‑efficiency gene integration for diverse biotech applications.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
A platform company delivering non‑viral, high‑efficiency gene integration for diverse biotech applications.
TherapeuticsBioprocessingAgricultureIndustrial Biotechnology
Technology Platform
Proprietary hyperactive integrase (KOMbine™/KOMbineX™) enabling precise, high‑efficiency insertion of large DNA payloads without double‑strand breaks.
Opportunities
Expansion into agricultural genome editing and large‑scale biologics manufacturing through licensing and collaborative development.
Risk Factors
Technology adoption risk, competition from CRISPR and viral platforms, and need for regulatory validation.
Competitive Landscape
Competes with CRISPR knock‑in, Sleeping Beauty, piggyBac, and viral vector systems; differentiates via high‑payload capacity and non‑viral, break‑free integration.